Impact of Treatment with Continuous Positive Airway Pressure (CPAP) on Weight in Obstructive Sleep Apnea

Stuart F. Quan, M.D., F.A.A.S.M.1;2; Rohit Budhiraja, M.D., F.A.A.S.M.2; Denise P. Clarke, B.Sc.; James L. Goodwin, Ph.D.3; Daniel J. Gottlieb, M.D., M.P.H., F.A.A.S.M.4; Deborah A. Nichols, M.S.3; Richard D. Simon, M.D., F.A.A.S.M.4; Terry W. Smith, B.S.2; James K. Walsh, Ph.D., F.A.A.S.M.5; Clete A. Kushida, M.D., F.A.A.S.M.6

1Division of Sleep Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA; 2Arizona Respiratory Center, University of Arizona, Tucson, AZ; 3Stanford, University, Stanford, CA; 4Providence St. Mary Medical Center, Walla Walla, WA; 5St. Luke’s Hospital, Chesterfield, MO; 6VA Boston Healthcare System, Boston, MA

Study Objective: To determine the impact of continuous positive airway pressure (CPAP) on weight change in persons with obstructive sleep apnea (OSA).

Design, Setting, and Participants: The Apnea Positive Pressure Long-term Efficacy Study (APPLES) was a 6-month, randomized, double-blinded sham-controlled multicenter clinical trial conducted at 5 sites in the United States. Of 1,105 participants with an apnea hypopnea index ≥ 10 events/hour initially randomized, 812 had body weight measured at baseline and after 6 months of study.

Intervention: CPAP or Sham CPAP.

Measurements: Body weight, height, hours of CPAP or Sham CPAP use, Epworth Sleepiness Scale score.

Results: Participants randomized to CPAP gained 0.35 ± 5.01 kg, whereas those on Sham CPAP lost 0.70 ± 4.03 kg (mean ± SD, p = 0.001). Amount of weight gain with CPAP was related to hours of device adherence, with each hour per night of use predicting a 0.42 kg increase in weight. This association was not noted in the Sham CPAP group. CPAP participants who used their device ≥ 4 h per night on ≥ 70% of nights gained the most weight over 6 months in comparison to non-adherent CPAP participants (1.0 ± 5.3 vs. -0.3 ± 5.0 kg, p = 0.014).

Conclusions: OSA patients using CPAP may gain a modest amount of weight with the greatest weight gain found in those most compliant with CPAP.

Keywords: Continuous positive airway pressure, weight, obstructive sleep apnea

Commentary: A commentary on this article appears in this issue on page 995.

Citation: Quan SF; Budhiraja R; Clarke DP; Goodwin JL; Gottlieb DJ; Nichols DA; Simon RD; Smith TW; Walsh JK; Kushida CA. Impact of treatment with continuous positive airway pressure (CPAP) on weight in obstructive sleep apnea. J Clin Sleep Med 2013;9(10):989-993.

BRIEF SUMMARY

Current Knowledge/Study Rationale: Obese OSA patients commonly believe that treatment with CPAP will facilitate weight loss. However, empirical observations and uncontrolled studies suggest otherwise. Data from randomized controlled studies are lacking.

Study Impact: In this 6 month randomized controlled trial, treatment with CPAP resulted in weight gain, not weight loss. Therefore, in addition to treatment with CPAP, obese OSA patients should engage in other behaviors such as increased physical activity and reduction in caloric intake to lose weight.

METHODS

Participants

The recruitment procedures and inclusion and exclusion criteria for APPLES have been described extensively. Briefly, APPLES was a multisite study conducted at 5 Clinical Centers: Stanford University, Stanford, CA; University of Arizona, Tucson, AZ; Providence St. Mary Medical Center, Walla Walla, WA; St. Luke’s Hospital, Chesterfield, MO; and Brigham and
Women’s Hospital, Boston, MA. The institutional review board (IRB) at each site approved the study protocol. Enrollment began in November 2003 and was completed in August 2008. All participants were adults with age ≥ 18 years and with an apnea hypopnea index (AHI) ≥ 10 events per hour. Excluded were individuals who had (1) prior OSA treatment with CPAP or surgery, (2) household members with current/past CPAP use, (3) a sleepiness-related automobile accident within the year prior to potential enrollment, (4) oxygen saturation < 75% for > 10% of the diagnostic polysomnogram (PSG) total sleep time; or (5) conditions or use of medications that could potentially affect neurocognitive function and/or alertness. For this analysis, only participants who had been randomized and had valid weight measurements at baseline and at the 6-month time point are included.

**Study Design**

The APPLES protocol has been described in detail elsewhere. In brief, participants were recruited from sleep clinics and by public advertisement. If an initial interview determined that there were no exclusion criteria, consenting participants underwent diagnostic PSG as previously described. Those who had an AHI ≥ 10/h and were not excluded because of severe oxygen desaturation were randomized to either active or sham CPAP (REMStar Pro, Phillips Respironics, Murrysville, PA) for 6 months. For those randomized to CPAP, the therapeutic pressure was determined during a sleep laboratory titration following their initial PSG. Those randomized to Sham underwent a sham PSG titration in the sleep laboratory. Neurocognitive assessments, the primary focus of the study, were performed at baseline and 2 and 6 months afterwards. The Epworth Sleepiness Scale was a component of the neurocognitive assessments. At these visits, weight measurements also were obtained using calibrated balance beam or digital scales, with the participant in street clothes without shoes. The same scale type was used at each visit. Height was measured at baseline using a stadiometer. Adherence to treatment was assessed objectively using Encore Pro SmartCards (Philips Respironics, Inc., Murrysville, PA), which were returned twice monthly.

### Table 1—Characteristics of APPLES participants with 6-month weight data

<table>
<thead>
<tr>
<th></th>
<th>Entire Cohort</th>
<th>Sham CPAP</th>
<th>Active CPAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>812</td>
<td>387</td>
<td>425</td>
</tr>
<tr>
<td>Age (years)</td>
<td>52.5 ± 12.0</td>
<td>52.1 ± 11.8</td>
<td>52.9 ± 12.1</td>
</tr>
<tr>
<td>% Male</td>
<td>64.6</td>
<td>64.2</td>
<td>64.9</td>
</tr>
<tr>
<td>% White</td>
<td>76.2</td>
<td>75.7</td>
<td>76.7</td>
</tr>
<tr>
<td>AHI (#/hour TST)</td>
<td>40.5 ± 25.0</td>
<td>41.3 ± 25.4</td>
<td>39.7 ± 24.7</td>
</tr>
<tr>
<td>% Severe OSA</td>
<td>57.1</td>
<td>58.3</td>
<td>56.0</td>
</tr>
<tr>
<td>BMI at Baseline (kg/m²)</td>
<td>32.2 ± 7.2</td>
<td>32.0 ± 6.8</td>
<td>32.4 ± 7.5</td>
</tr>
<tr>
<td>Weight at Baseline (kg)</td>
<td>96.3 ± 22.4</td>
<td>95.7 ± 20.9</td>
<td>96.8 ± 23.7</td>
</tr>
<tr>
<td>Epworth Sleepiness Scale at Baseline</td>
<td>10.4 ± 4.5</td>
<td>10.4 ± 4.4</td>
<td>10.3 ± 4.5</td>
</tr>
<tr>
<td>Hours Used/Night</td>
<td>4.2 ± 2.3</td>
<td>3.5 ± 2.2</td>
<td>4.8 ± 2.1 a</td>
</tr>
<tr>
<td>% Adherent</td>
<td>35.9</td>
<td>25.1</td>
<td>45.7 a</td>
</tr>
</tbody>
</table>

*p < 0.001 Sham vs. CPAP. aN = 707 (Sham: 335, CPAP: 372).

**Statistical Analyses**

Body mass index (BMI) was computed as weight (kg)/height (m)². Participants’ race/ethnicity were classified as self-reported white or non-white. Assessment of adherence to CPAP or Sham used data obtained during the 1 month prior to the 6-month visit and was expressed as the mean hours of nightly use. Classification of participants as adherent or non-adherent was based on whether they used their assigned treatment > 4 h on ≥ 70% of nights. For continuous variables, unadjusted comparisons between CPAP and Sham were made using Students’ t-test. Differences in proportions were assessed using the χ² test. Repeated measures analysis of variance and covariance and linear regression were used to determine the impact of treatment group as well as other possible factors on weight change over the 6-month timeframe of the study. Data are expressed as mean ± standard deviation (SD) or percentages. Analyses were performed using IBM SPSS Statistics Version 20 (Chicago, IL).

**RESULTS**

There were 1,105 participants initially randomized, but 7 were later excluded because they were later found to be ineligible or inadvertently received both study arms. Another 286 were excluded for missing measurements of body weight at 6 months. Of the remaining 812 participants, 387 had been randomized to Sham and 425 to active CPAP. There were no differences in baseline weight, height, gender, race, AHI, or ESS between participants with and without 6-month weight measurements. However, participants who had 6-month weight data were slightly older (52.5 ± 12.2 vs. 48.9 ± 12.4 years, p < 0.001). As shown in **Table 1**, participants generally were middle-aged, white, male, and obese. They also had moderate to severe OSA, were mildly sleepy, and had suboptimal adherence to their assigned treatment. There were no differences between the 2 groups with respect to age, gender, race, OSA severity, weight, BMI, or Epworth Sleepiness Scale score. However, participants in the Sham group were generally less adherent to their assigned treatment.

The changes in weight from baseline to the 6-month time point for the Sham and CPAP groups are shown in **Figure 1**.
Participants in the Sham group had a slight decrease in their weight, whereas those in the CPAP group had a slight increase. This difference in weight change was statistically significant (Sham = -0.70 ± 4.03 vs CPAP = 0.35 ± 5.01 kg, p = 0.001). There was no effect modification related to age, gender, race, baseline BMI, OSA severity, or ESS score, and these factors were not included in subsequent analytic models. However, change in weight was associated with adherence in the CPAP group, with each hour per night of CPAP use associated with a mean 0.42 kg increase in weight over 6 months (p = 0.001). In contrast, there was no association between weight change and adherence in the Sham group.

Table 2 shows mean baseline and 6-month weights stratified by treatment group and treatment adherence. There were 707 participants with analyzable adherence data. When classified by whether participants had 70% of nights with > 4 hours use, strikingly, adherent CPAP participants had a mean 1 kg increase in weight (97.0 ± 20.1 vs. 98.0 ± 25.6 kg, p = 0.014). In contrast, non-adherent Sham participants had a slight decrease in weight (96.3 ± 21.7 vs. 95.6 ± 21.7, p = 0.008).

**DISCUSSION**

In this study we found that treatment of OSA with CPAP did not result in a reduction in weight, and actually was associated with weight gain. This observation was independent of age, gender, race, OSA severity, and sleepiness. Furthermore, those with the greatest adherence to CPAP appeared to have gained the most weight.

The primary finding in this study is that CPAP treatment of OSA does not result in weight loss over a 6-month time frame. Our findings are therefore consistent with those of Redenius et al., who failed to observe in a retrospective study any reduction in weight in 183 CPAP treated patients followed in a sleep center over 10 to 14 months. Similarly, several smaller studies also have failed to find a change in weight with CPAP treatment. In a randomized controlled trial of sibutramine in comparison to CPAP for weight loss, CPAP treatment for one year in 18 patients was not associated with a change in weight. Similarly, addition of CPAP did not result in greater weight loss when used as adjunctive therapy for a behavioral weight loss program in OSA patients. In two other randomized controlled studies of CPAP compared to sham CPAP, CPAP treatment for 12 weeks or 24 weeks also did not result in weight loss. However, the latter four studies may have been inadequately powered to detect a small change in weight. In a much larger, although non-blinded randomized study, CPAP treatment for a median of four years failed to result in weight loss. In contrast, Loube et al. observed that in 21 CPAP-treated OSA patients, those who self-reported being adherent were more likely to have greater than a 4.5 kg weight loss than those non-adherent. However, there was no significant weight change for the group overall. More recently, Sharma and colleagues in a randomized cross-over design of 86 participants found that CPAP treatment for 3 months resulted in a mean weight loss of 0.37 kg compared to a 0.33 kg weight gain with sham CPAP. Our study of 812 participants is considerably larger than all but one of the aforementioned investigations and would be more likely to detect small changes in weight. Thus our results do not support the hypothesis that CPAP treatment of OSA facilitates weight loss.

We observed that aside from adherence to treatment assignment, no other factors modified the association between CPAP (or sham CPAP) and change in weight. In contrast, Redenius
et al. found that women were more likely to gain weight after CPAP use. However, their data were derived retrospectively from a clinical population, whereas APPLES participants were largely recruited from the community. Thus, participant characteristics may account for this different observation.

In our study, participants treated with CPAP not only failed to lose weight, but actually appeared to gain a small amount of weight. Moreover, we found that those who were adherent to CPAP gained weight over six months of therapy in contrast to no significant weight increase observed in the sham or non-adherent CPAP participants. Furthermore, there was a dose response relationship between hours of adherence and amount of weight gained. These findings are consistent with Redenius et al., who found that in a subgroup analysis, those who used CPAP for more than 7 hours per night on 90% of nights had an increase in their BMI. Furthermore, in a small randomized controlled study, Garcia et al. observed a small amount of weight gain in 20 obese OSA subjects over the course of 6 months. Our study extends these latter findings by documenting weight gain with CPAP in a much larger cohort and showing that it is a function of adherence. Thus, our findings and those of previous studies suggest that CPAP is inducing a state of positive energy balance resulting in weight gain.

There are several mechanisms related to energy expenditure (EE) that could explain why persons treated with CPAP gain weight. Weight gain occurs when energy intake (EI) exceeds EE. Some but not all studies indicate that resting 24-hour as well as sleep EE in persons with OSA are higher than in those without OSA. Furthermore, EE may be higher in those with greater severity of OSA. Elevated EE during sleep in OSA patients may be related to greater work of breathing, similar to that observed in patients with chronic obstructive lung disease. Alternatively, there may be greater activation of the sympathetic nervous system as a result of more frequent arousals and intermittent hypoxia. Intervention with CPAP as well as upper airway surgery has been shown to reduce sleep EE, and in the absence of change in energy intake would favor weight gain. Alterations in level of physical activity and dietary habits with CPAP also could change the balance between EI and EE in OSA. Although patients with OSA often indicate that sleepiness and lack of energy are barriers to increased physical activity, a recent study observed that intervention with CPAP for three months improved sleepiness but did not alter activity levels. Inflammatory cytokines are elevated in OSA and decrease with use of CPAP. They may promote anorexia, and thus CPAP might reduce this effect leading to weight gain. However, we have previously demonstrated in APPLES that OSA participants eat high-caloric atherogenic diets. Preliminary data from a four-month follow-up of these participants indicate that their dietary habits do not change after intervention with CPAP. Thus, available evidence suggests that CPAP reduces sleep EE, but there is no corresponding increase in daytime EE or decrease in EI. This results in an energy balance that favors weight gain.

Fluid retention related to elevations in intrathoracic pressure from CPAP could explain some of the weight gain. In both clinical and experimental studies, positive airway pressure results in fluid retention related to a reduction in venous return and decreased secretion of antidiuretic hormone and atrial natriuretic peptide. However, any contribution from fluid retention is likely to be minor because CPAP is not used during wakefulness in OSA.

Our study is not without limitations. First, overall adherence to both treatment arms was suboptimal. However, the levels of adherence in this study are similar to those in other long-term randomized controlled trials. Furthermore, given our current findings, greater adherence would likely have made the differences in weight between CPAP and Sham even more striking. Second, in comparison to the CPAP group, more participants in the Sham group failed to complete the study. Differential dropout of Sham participants who were more likely to gain weight might explain the difference between the two groups, although there is no evidence that this occurred. Third, because the primary focus of this study was on neurocognitive outcomes, we did not collect data such as direct energy expenditure measurements, which might validate proposed mechanisms underlying the increase in weight observed in CPAP participants. Lastly, most of our participants were recruited from the community and not a sleep clinic. Thus, our findings may not be representative of the patient population seen in a clinical setting. Despite these limitations, our study had a number of strengths, including the large number of participants, a long 6-month follow-up period, use of sham CPAP as a control, and objective documentation of adherence to therapy.

In conclusion, treatment of OSA with CPAP may result in modest weight gain. Thus, if overweight, OSA patients should be encouraged to lose weight by other modalities and not rely on any direct physiologic effect of CPAP.

REFERENCES

died before the results of this trial were analyzed, but was instrumental in its design.

American Academy of Sleep Medicine and the Sleep Medicine Education and Research Institute. The APPLES pilot studies were supported by grants from the National Heart, Lung, and Blood Institute.


**ACKNOWLEDGMENTS**

APPLES was funded by contract 5U01-HL-068060 from the National Heart, Lung and Blood Institute. The APPLES pilot studies were supported by grants from the American Academy of Sleep Medicine and the Sleep Medicine Education and Research Foundation to Stanford University and by the National Institute of Neurological Disorders and Stroke (N44-NS-002394) to SAM Technology. In addition, APPLES investigators gratefully recognize the vital input and support of Dr. Sylvan Green who died before the results of this trial were analyzed, but was instrumental in its design and conduct.

**Administrative Core:** Clete A. Kushida, MD, PhD; Deborah A. Nichols, MS; Eileen B. Leary, BA, RPSGT; Pamela R. Hyde, MA; Tyson H. Holmes, PhD; Daniel A. Bloch, PhD; William C. Dement, MD, PhD

**Data Coordinating Center:** Daniel A. Bloch, PhD; Tyson H. Holmes, PhD; Deborah A. Nichols, MS; Rik Jadamicke, Microflow, Ric Millor, Microflow Usman Ajaji, MS; Aamir Farooq, PhD; Darryl Thomander, PhD; Chia-Yu Cardell, RPSGT; Emily Kees, Michael E. Sorel, MPH; Oscar Carrillo, RPSGT; Tami Crabtree, MS; Booli Jo, PhD; Ray Balise, PhD; Tracy Kuo, PhD

**Clinical Coordinating Center:** Clete A. Kushida, MD, PhD, William C. Dement, MD, PhD, Pamela R. Hyde, MA, Rhonda M. Wong, BA, Pete Silva, Max Harshkowitz, PhD, Alan Gevins, DSc, Gary Kay, PhD, Linda K. McEvoy, PhD, Cynthia S. Chan, BS, Sylvan Green, MD

**Clinical Centers:** Stanford University: Christian Guilleminault, MD; Eileen B. Leary, BA, RPSGT; David Claman, MD; Stephen Brooks, MD; Julienne Blythe, PA-C, RPSGT; Jennifer Blair, BA; Pam Simi, Ronelle Broussard, BA, Emily Greenberg, MPH; Bethany Franklin, MS; Amirah Khouzam, MA; Sangana Behari Black, BS, RPSGT; Viola Arias, RPSGT; Romelyn Delos Santos, BS; Tara Tanaka, PhD

University of Arizona: Stuart F. Quan, MD; James L. Goodwin, PhD; Wei Shen, MD; Phillip Eichling, MD; Rohit Budhiraj, MD; Charles Wynstra, MBA; Cathy Ward, Colleen Dunn, BS; Terry Smith, BS; Dane Holderman, Michael Robinson, BS; Osmara Molina, BS; Aaron Ostrovsky, Jesus Wences, Sean Prielfert, Julia Rogers, BS; Megan Ruitler, BS; Leslie Crosby, BS, RN

St. Mary Medical Center: Richard D. Simon Jr., MD; Kevin Hurlbert, RPSGT, Michael Bernstein, MD; Timothy Davidson, MD; Jeanine Oroc-Takele, RPSGT; Shelly Rubin, MA; Philip Smith, RPSGT; Erica Roth, RPSGT; Julie Flaa, RPSGT; Jennifer Blalr, BA; Jennifer Schwartz, BA; Anna Simon, BA; Amber Randall, BA

St. Luke’s Hospital: James K. Walsh, PhD, Paula K. Schweitzer, PhD, Anup Katyal, MD, Rhodes Eisenstein, MD, Stephen Feren, MD, Nancy Cline, Dena Robertson, RN, Sheri Compton, RN, Susan Greene, Kara Griffin, MS, Janine Hall, PhD

Bigham and Women’s Hospital: Daniel J. Gottlieb, MD, MHP, David P. White, MD, Denise Clarke, BSc, RPSGT, Kevin Moore, BA, Grace Brown, BA, Paige Hardy, MS, Kerry Eudy, PhD, Lawrence Epstein, MD, Sanjay Patel, MD

The authors also acknowledge Sleep HealthCenters for the use of their clinical facilities to conduct this research.

**Consultant Teams:**

Methodology Team: Daniel A. Bloch, PhD, Sylvan Green, MD, Tyson H. Holmes, PhD, Maurice M. Olayon, MD, DSc, David White, MD, Terry Young, PhD

Sleep Disordered Breathing Protocol Team: Christian Guilleminault, MD, Stuart Quan, MD, David White, MD

EEG/Neurocognitive Function Team: Jed Black, MD, Alan Gevins, DSc, Max Hirshkowitz, PhD, Gary Kay, PhD, Tracy Kuo, PhD

Mood and Sleepiness Assessment Team: Ruth Benca, MD, PhD, William C. Dement, MD, PhD, Karl Doghramji, MD, Tracy Kuo, PhD, James K. Walsh, PhD Quality of Life Assessment Team: W. Ward Flemons, MD, Robert M. Kaplan, PhD

APPLES Secondary Analysis-Neurocognitive (ASA-NC) Team: Dean Beebe, PhD, Robert Heaton, PhD, Joel Kramer, PsyD, Ronald Lazard, PhD, David Loewenstein, PhD, Frederick Schmitt, PhD

National Heart, Lung, and Blood Institute (NHLBI)

Michael J. Twery, PhD, Gail Weinmann, MD, Colin H. Wu, PhD

**Data and Safety Monitoring Board (DSMB)**

Seven year term: Richard J. Martin, MD, PhD, Charles F. Emery, PhD, Susan M. Harding MD, John M. Lachin, ScD, Phyllis C. Zee, MD, PhD

Other term: Xihong Lin, PhD (2 years), Thomas H. Murray, PhD (1 year)

**SUBMISSION & CORRESPONDENCE INFORMATION**

Submitted for publication April, 2013
Submitted in final revised form June, 2013
Accepted for publication June, 2013

Address correspondence to: Stuart F. Quan, M.D., Division of Sleep Medicine, Harvard Medical School, 401 Park Dr., 2nd Floor East, Boston, MA 02215; Tel: (617) 998-8842; Fax: (617) 998-8823; E-mail: squan@arc.arizona.edu

**DISCLOSURE STATEMENT**

This was not an industry supported study. Dr. Quan is the Editor-in-Chief of the *Journal of Clinical Sleep Medicine*. The other authors have indicated no financial conflicts of interest.

993 Journal of Clinical Sleep Medicine, Vol. 9, No. 10, 2013